National Planning Corp cut its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 32.9% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,823 shares of the biotechnology company’s stock after selling 2,850 shares during the period. National Planning Corp’s holdings in Sarepta Therapeutics were worth $203,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in SRPT. C WorldWide Group Holding A S boosted its stake in Sarepta Therapeutics by 2,404.1% in the first quarter. C WorldWide Group Holding A S now owns 82,735 shares of the biotechnology company’s stock worth $2,449,000 after buying an additional 79,431 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Sarepta Therapeutics by 24.4% in the first quarter. Wells Fargo & Company MN now owns 84,710 shares of the biotechnology company’s stock worth $2,508,000 after buying an additional 16,620 shares in the last quarter. Emerald Advisers Inc. PA boosted its stake in Sarepta Therapeutics by 49.2% in the first quarter. Emerald Advisers Inc. PA now owns 818,705 shares of the biotechnology company’s stock worth $24,234,000 after buying an additional 270,134 shares in the last quarter. Emerald Mutual Fund Advisers Trust boosted its stake in Sarepta Therapeutics by 50.2% in the first quarter. Emerald Mutual Fund Advisers Trust now owns 604,467 shares of the biotechnology company’s stock worth $17,892,000 after buying an additional 201,942 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in Sarepta Therapeutics by 63.9% in the first quarter. Russell Investments Group Ltd. now owns 38,273 shares of the biotechnology company’s stock worth $1,133,000 after buying an additional 14,919 shares in the last quarter. 63.11% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) opened at 37.43 on Thursday. The stock’s market capitalization is $2.41 billion. The company has a 50-day moving average of $37.29 and a 200 day moving average of $32.99. Sarepta Therapeutics, Inc. has a one year low of $24.75 and a one year high of $63.73.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.46. The business had revenue of $35.01 million during the quarter, compared to analyst estimates of $22.52 million. During the same period in the previous year, the business posted ($1.19) earnings per share. The firm’s quarterly revenue was up 350000.0% on a year-over-year basis. Equities research analysts forecast that Sarepta Therapeutics, Inc. will post ($1.16) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Sarepta Therapeutics, Inc. (SRPT) Shares Sold by National Planning Corp” was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/sarepta-therapeutics-inc-srpt-shares-sold-by-national-planning-corp/1497720.html.

A number of research firms recently issued reports on SRPT. Janney Montgomery Scott lifted their price target on shares of Sarepta Therapeutics from $65.00 to $73.00 and gave the company a “fair value” rating in a research note on Monday, July 24th. Morgan Stanley reissued an “equal weight” rating and issued a $33.00 price target (up previously from $31.00) on shares of Sarepta Therapeutics in a research note on Thursday, July 20th. Robert W. Baird reissued an “outperform” rating and issued a $96.00 price target (down previously from $102.00) on shares of Sarepta Therapeutics in a research note on Friday, July 21st. William Blair reissued an “outperform” rating on shares of Sarepta Therapeutics in a research note on Thursday, July 27th. Finally, Zacks Investment Research raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. Eight investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $61.28.

In other Sarepta Therapeutics news, CEO Douglas S. Ingram purchased 47,058 shares of the firm’s stock in a transaction on Thursday, July 27th. The shares were purchased at an average cost of $42.50 per share, with a total value of $1,999,965.00. Following the purchase, the chief executive officer now owns 382,058 shares in the company, valued at $16,237,465. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Alexander Cumbo sold 5,918 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $242,638.00. Following the completion of the sale, the senior vice president now directly owns 22,793 shares in the company, valued at $934,513. The disclosure for this sale can be found here. Over the last three months, insiders sold 78,056 shares of company stock worth $3,224,208. 9.60% of the stock is owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.